Boundless Bio (BOLD) Cash from Financing Activities (2023 - 2025)
Boundless Bio (BOLD) posted quarterly Cash from Financing Activities of $24000.0 for Q4 2025, down 78.76% year-over-year from $113000.0 in Q4 2024, and down 78.76% quarter-over-quarter from $113000.0 in Q4 2024.
Boundless Bio (BOLD) Cash from Financing Activities (2023 - 2025) Analysis & Trends
Boundless Bio (BOLD) has reported Cash from Financing Activities for 3 consecutive years, with $24000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 78.76% year-over-year to $24000.0; the TTM figure through Dec 2025 stood at $124000.0 (down 99.86% YoY), while the FY2025 annual figure was $141000.0, down 99.84% from the prior year.
- Cash from Financing Activities eased to $24000.0 in Q4 2025 per BOLD's latest filing, from $113000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $99.7 million in Q2 2023 and bottomed at -$1.4 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged $20.9 million across 3 years, with a median of $24000.0 in 2025.
- On a YoY basis, Cash from Financing Activities climbed as much as 108.16% in 2024 and fell as far as 3080.65% in 2024.
- Boundless Bio's Cash from Financing Activities stood at -$1.4 million in 2023, then jumped by 108.16% to $113000.0 in 2024, then sank by 78.76% to $24000.0 in 2025.
- Business Quant data shows BOLD's Cash from Financing Activities at $24000.0 in Q4 2025, $113000.0 in Q4 2024, and -$13000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24,000.00 |
| Dec 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 113,000.00 |
| Dec 31, 2024 | 113,000.00 |
| Sep 30, 2024 | -13,000.00 |
| Sep 30, 2024 | -13,000.00 |
| Jun 30, 2024 | 90.65 Mn |
| Jun 30, 2024 | 90.65 Mn |
| Mar 31, 2024 | -924,000.00 |
| Mar 31, 2024 | -924,000.00 |
| Dec 31, 2023 | -1.38 Mn |
| Dec 31, 2023 | -1.38 Mn |
| Sep 30, 2023 | -447,000.00 |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | 99.70 Mn |
| Jun 30, 2023 | 99.70 Mn |
| Mar 31, 2023 | 31,000.00 |
| Mar 31, 2023 | 31,000.00 |